申请人:Medivation Technologies, Inc.
公开号:US20130190347A1
公开(公告)日:2013-07-25
This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
本公开涉及新的三环化合物,可用于调节个体中的组胺受体。其中包括新的2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物。此外还提供了包含这些化合物的制药组合物,以及使用这些化合物治疗各种治疗应用的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。